<DOC>
	<DOCNO>NCT01237951</DOCNO>
	<brief_summary>The goal clinical research study learn combination gemcitabine , busulfan , melphalan , give stem cell transplant , help control refractory myeloma . The safety study treatment also study .</brief_summary>
	<brief_title>High-Dose Gemcitabine , Busulfan Melphalan With Hematopoietic-Cell Support Patients With Poor-Risk Myeloma</brief_title>
	<detailed_description>Study Drugs : Busulfan melphalan design bind DNA ( genetic material ) cell , may cause cancer cell die . They commonly use stem cell transplantation . Gemcitabine design disrupt growth cancer cell , may cause cancer cell die . It may help increase effect busulfan melphalan cancer cell allow cell repair DNA damage cause busulfan melphalan . Busulfan Test Dose : You receive test dose busulfan vein 60 minute . This low-level test dose busulfan check level busulfan blood level change time . This information use decide next dose need reach target blood level match body size . You likely receive outpatient week admit hospital . If give outpatient , admitted hospital Day -11 ( 11 day stem cell return body ) test dose give Day -10 . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point help study doctor determine dose busulfan study . These blood sample draw various timepoints receive busulfan next 11 hour . The blood sample repeat first day high-dose busulfan treatment Day -8 . A temporary heparin lock line place vein low number needle stick need draws . If possible PK test perform , receive standard dose busulfan . If receive busulfan test dose outpatient : On Days -12 ( 12 day stem cell return body ) Day -10 , receive palifermin vein 30 second help decrease risk side effect mouth throat . You admit Day -9 receive fluid vein hydrate . You swish liquid caphosol glutamine mouth 4 time day , 2 minute time . You swish liquid every day leave hospital . These drug also use help decrease risk side effect mouth throat . On Days -8 -5 , receive busulfan vein 3 hour . On Days -8 -3 , receive gemcitabine vein 3 hour . On Day -4 , receive drug . If receive busulfan test dose inpatient : On Days -13 Day -11 , receive palifermin vein 30 second day help decrease risk side effect mouth throat . You admit Day -11 receive fluid vein hydrate . You swish liquid caphosol glutamine mouth 4 time day , 2 minute time . You swish liquid every day leave hospital . These drug also use help decrease risk side effect mouth throat . On Day -10 , receive busulfan test dose vein 45 minute . On Day -9 , receive drug . On Days -8 -3 , receive gemcitabine vein 3 hour day . On Days -8 -5 , receive busulfan vein 3 hour day . Study Drug Administration ( patient ) : On Days -9 -2 , receive dexamethasone vein 15 minute help decrease risk possible side effect study drug . On Days -3 -2 , receive melphalan vein 30 minute day . On Day -1 , receive drug . On Day 0 , stem cell return body vein 30-60 minute . On Days 0 2 , receive palifermin vein 30 second day . Beginning Day 5 , receive filgrastim ( drug help growth white blood cell ) needle skin 1 time day blood cell level return normal . Study Tests : While hospital , check side effect part standard care . Blood ( 2 teaspoon ) draw every day check side effect . As part standard care , remain hospital 3-4 week transplant . After release hospital , must remain Houston area monitor infection transplant side effect Day 30 . During time , return clinic 1 time week follow test procedure perform : - You ask feel side effect may . - Blood ( 2 teaspoon ) draw routine test . - You lung function test 30-100 day transplant . Length Study : You follow part study least 2 year . You may take study early disease get bad experience intolerable side effect . At follow-up visit follow test procedure perform : - Your medical history record . - You physical exam . - Blood ( 2 teaspoon ) urine collect routine test . - If doctor think need , bone marrow biopsy check status disease . - Bone survey : Only year . You must talk study doctor want leave study early . It may life-threatening leave study begin receive study drug receive stem cell . This investigational study . Busulfan , gemcitabine , melphalan FDA approve commercially available treatment lymphoma , myeloma , several tumor . The use study drug together use gemcitabine dose level use study investigational . Up 75 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Age 18 70 year . 2 . Patients myeloma treat firstline therapy include lenalidomide , bortezomib thalidomide , one following : 2.1 ) M paraprotein great 1 g/dL HDC . 2.2 ) Less partial response firstline therapy . 2.3 ) Relapse firstline therapy . 2.4 ) Relapse prior autologous stemcell transplant . 3 . Adequate renal function , define serum creatinine &lt; /=1.8 mg/dL and/or estimate serum creatinine clearance &gt; /=50 ml/min 4 . Adequate hepatic function , define SGOT and/or SGPT &lt; /=3 x upper limit normal ; serum bilirubin alkaline phosphatase &lt; /=2 x upper limit normal , unless prove due disease involvement . 5 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /=50 % expect corrected hemoglobin and/or volume . 6 . Adequate cardiac function leave ventricular ejection fraction &gt; /=40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 7 . Zubrod performance status &lt; 2 . 8 . Negative Beta HCG text woman childbearing potential , define postmenopausal 12 month previous surgical sterilization 1 . Patients grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= grade 1 . 2 . Patients prior whole brain irradiation 3 . Patients active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . Active infection require parenteral antibiotic . 6 . HIV infection , unless patient receive effective antiretroviral therapy undetectable viral load normal CD4 count 7 . Patients receive radiation therapy head neck ( exclude eye ) , internal organ chest , abdomen pelvis month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Autologous Hematopoietic-Cell Support</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Myleran</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Decadron</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>